Ale Algra

Ale Algra

Auto-generated profile, based on publicly available information

Ale Algra

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
GRGabriel Je Rinkel
Gabriel Je Rinkel
AAAle Algra
Ale Algra

1 May 2007 in Epilepsia
Verified
Journal Article
Closed access
PDF file
FJFloor E. Jansen
Floor E. Jansen
AHAlexander. C. Van Huffelen
Alexander. C. Van Huffelen
AAAle Algra
Ale Algra
ONOnno Van Nieuwenhuizen
Onno Van Nieuwenhuizen

8 July 2013 in Trials
Verified
Journal Article
Open access
PDF file
EHErik Jrj van der Hoeven
Erik Jrj van der Hoeven
WSWouter J Schonewille
Wouter J Schonewille
JVJan Albert Vos
Jan Albert Vos
AAAle Algra
Ale Algra
HAHeinrich J Audebert
Heinrich J Audebert
JKJaap L Kappelle
Jaap L Kappelle
Background: Despite recent advances in acute stroke treatment, basilar artery occlusion (BAO) is associated with a death or disability rate of close to 70%. Randomised trials have shown the safety and efficacy of intravenous thrombolysis (IVT) given within 4.5 h and have shown promising results of intra-arterial thrombolysis given within 6 h of symptom onset of acute ischaemic stroke, but these results do not directly apply to patients with an acute BAO because only few, if any, of these patients were included in randomised acute stroke trials. Recently the results of the Basilar Artery International Cooperation Study (BASICS), a prospective registry of patients with acute symptomatic BAO challenged the often-held assumption that intra-arterial treatment (IAT) is superior to IVT. Our observations in the BASICS registry underscore that we continue to lack a proven treatment modality for patients with an acute BAO and that current clinical practice varies widely. Design: BASICS is a randomised controlled, multicentre, open label, phase III intervention trial with blinded outcome assessment, investigating the efficacy and safety of additional IAT after IVT in patients with BAO. The trial targets to include 750 patients, aged 18 to 85 years, with CT angiography or MR angiography confirmed BAO treated with IVT. Patients will be randomised between additional IAT followed by optimal medical care versus optimal medical care alone. IVT has to be initiated within 4.5 h from estimated time of BAO and IAT within 6 h. The primary outcome parameter will be favourable outcome at day 90 defined as a modified Rankin Scale score of 0–3. Discussion: The BASICS registry was observational and has all the limitations of a non-randomised study. As the IAT approach becomes increasingly available and frequently utilised an adequately powered randomised controlled phase III trial investigating the added value of this therapy in patients with an acute symptomatic BAO is needed (clinicaltrials.gov: NCT01717755).

20 June 2019 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MVM.D.I. Vergouwen
M.D.I. Vergouwen
DBD. Backes
D. Backes
ISI.C. van der Schaaf
I.C. van der Schaaf
JHJ. Hendrikse
J. Hendrikse
RKR. Kleinloog
R. Kleinloog
GRG.J.E. Rinkel
G.J.E. Rinkel
BACKGROUND AND PURPOSE: Previous studies have suggested that gadolinium enhancement of the wall of unruptured intracranial aneurysms on MR imaging may reflect aneurysm wall instability. However, all previous studies were cross-sectional. In this longitudinal study, we investigated whether aneurysm wall enhancement is associated with an increased risk of aneurysm instability. MATERIALS AND METHODS: We included all patients 18 years of age or older with ≥1 unruptured aneurysm from the University Medical Center Utrecht, the Netherlands, who were included in 2 previous studies with either 3T or 7T aneurysm wall MR imaging and for whom it was decided not to treat the aneurysm but to monitor it with follow-up imaging. We investigated the risk of growth or rupture during follow-up of aneurysms with and without gadolinium enhancement of the aneurysm wall at baseline and calculated the risk difference between the 2 groups with corresponding 95% confidence intervals. RESULTS: We included 57 patients with 65 unruptured intracranial aneurysms. After a median follow-up of 27 months (interquartile range, 20–31 months), growth (n = 2) or rupture (n = 2) was observed in 4 of 19 aneurysms (21%; 95% CI, 6%–54%) with wall enhancement and in zero of 46 aneurysms (0%; 95% CI, 0%–8%) without enhancement (risk difference, 21%; 95% CI, 3%–39%). CONCLUSIONS: Gadolinium enhancement of the aneurysm wall on MR imaging is associated with an increased risk of aneurysm instability. The absence of wall enhancement makes it unlikely that the aneurysm will grow or rupture in the short term. Larger studies are needed to investigate whether aneurysm wall enhancement is an independent predictor of aneurysm instability.

9 June 2005 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
ASA. J. C. Slooter
A. J. C. Slooter
FRF. R. Rosendaal
F. R. Rosendaal
BTB. C. Tanis
B. C. Tanis
JKJ. M. Kemmeren
J. M. Kemmeren
YGY. VAN DER Graaf
Y. VAN DER Graaf
AAA. Algra
A. Algra
Summary. Background: The role of inherited prothrombotic conditions, including factor V Leiden (FV G1691A), prothrombin G20210A, and the methylenetetrahydrofolate reductase (MTHFR) C677T genotype, in the pathogenesis of ischemic stroke is not well established. The effects of these factors may be potentiated by the use of oral contraceptives, analogous to observations in venous thrombosis. Methods: Patients (n = 193) were women aged 20–49 years with ischemic stroke. Controls (n = 767) were women without arterial thrombosis stratified for age, calendar year of the index event, and residence. The relative risk of ischemic stroke was estimated with unconditional logistic regression, adjusted for stratification variables. Findings: Factor V Leiden and MTHFR 677TT were more common in patients than in controls [odds ratio (OR): 1.8; 95% confidence interval (CI): 0.9–3.6 respectively OR: 1.5; 95% CI: 0.9–2.6]. The frequency of prothrombin G20210A was similar in cases and controls. Carriers of FV Leiden using oral contraceptives had a 11.2-fold (95% CI: 4.3–29.0) higher risk of ischemic stroke than women without either risk factor. Women with MTHFR 677TT using oral contraceptives had a 5.4-fold (95% CI: 2.4–12.0) higher risk than women without these risk factors. Interpretation: These data suggest that carriers of FV Leiden or MTHFR 677TT who use oral contraceptives have an increased risk of ischemic stroke. When these findings are confirmed, a cost-effectiveness analysis should indicate whether ischemic stroke could be prevented with genetic testing before the start of oral contraceptives.

11 September 2006 in Trials
Verified
Journal Article
Open access
PDF file
TIthe HAMLET investigators
the HAMLET investigators
JHJeannette Hofmeijer
Jeannette Hofmeijer
GAG Johan Amelink
G Johan Amelink
AAAle Algra
Ale Algra
JGJan van Gijn
Jan van Gijn
HWH Bart van der Worp
H Bart van der Worp
Patients with a hemispheric infarct and massive space-occupying brain oedema have a poor prognosis. Despite maximal conservative treatment, the case fatality rate may be as high as 80%, and most survivors are left severely disabled. Non-randomised studies suggest that decompressive surgery reduces mortality substantially and improves functional outcome of survivors. This study is designed to compare the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction The study design is that of a multi-centre, randomised clinical trial, which will include 112 patients aged between 18 and 60 years with a large hemispheric infarct with space-occupying oedema that leads to a decrease in consciousness. Patients will be randomised to receive either decompressive surgery in combination with medical treatment or best medical treatment alone. Randomisation will be stratified for the intended mode of conservative treatment (intensive care or stroke unit care). The primary outcome measure will be functional outcome, as determined by the score on the modified Rankin Scale, at one year.